BioVaxys Technology Corp. has joined The Rapid Response Partnership Vehicle (RRPV), a consortium of biopharma, contractors, government agencies, and research institutions that support the US Government’s Biomedical Advanced Research and Development Authority (BARDA) in its objective to accelerate Medical Countermeasure product and technology development to address evolving needs including pandemic influenza, emerging infectious diseases, and other biological threats.
 
The RRPV is a multi-purpose acquisition vehicle for developing medical countermeasures from early to advanced stages, including procurement and commercialization. It aims to accelerate acquisition and partnerships in response to pandemics and biothreats while promoting innovation in medical countermeasures and technologies to enhance national health security.
 
A key focus is enabling targeted expertise in vaccine and therapeutic development. Consortium members are invited to submit proposals to BARDA, which will evaluate them and authorize project agreements for individual projects.
 
The RRPV enhances BARDA’s current solicitation mechanisms like the Broad Agency Announcement (BAA), allowing rapid partnerships with product developers in areas of interest, such as advanced flu vaccines and technologies for quicker vaccine development.
 
BioVaxys President and Chief Operating Officer Kenneth Kovan, says, “We are pleased to join the RRPV consortium with organizations including AstraZeneca, Battelle, Deutsches Zentrum für Infektionsforschung e.V. (The German Center for Infection Research), Genentech, Ginkgo Bioworks Inc., Novavax and Leidos. We believe DPX can play a major role in the development of BARDA’s priority vaccine programs, and having the ability to collaborate with such world-renowned consortium members will no doubt be a significant benefit for the company.”